Format

Send to

Choose Destination
Pain Manag. 2018 Nov 1;8(6):415-426. doi: 10.2217/pmt-2018-0037. Epub 2018 Sep 21.

Erenumab in the treatment of migraine.

Author information

1
Department of Pain Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.
2
Department of Neurology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.
3
Jefferson Headache Center, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.

Abstract

Migraine is a highly prevalent neurological pain syndrome, and its management is limited due to side effects posed by current preventive therapies. Calcitonin gene-related peptide (CGRP) plays a crucial role in the pathogenesis of migraine. In recent years, research has been dedicated to the development of monoclonal antibodies against CGRP and CGRP receptors for the treatment of migraine. This review will focus on the first US FDA-approved CGRP-receptor monoclonal antibody developed for the prevention of migraine: erenumab. Two Phase II trials (one for episodic migraine and one for chronic migraine) and two Phase III trials for episodic migraine have been published demonstrating the efficacy and safety of erenumab in the prevention of migraine.

KEYWORDS:

AMG 334; Aimovig™; CGRP; CGRP monoclonal antibody; CGRP receptor; FDA-approved migraine treatment; erenumab; migraine; migraine prophylaxis; new migraine treatment

PMID:
30235976
DOI:
10.2217/pmt-2018-0037
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center